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Introduction {#ijc32498-sec-0001}
============

Somatic mutation signatures act as the physiological readout of the biological history of a cancer, and provide a new bridge to connect cancer mutation to both exogenous and endogenous risk factors.[1](#ijc32498-bib-0001){ref-type="ref"}, [2](#ijc32498-bib-0002){ref-type="ref"}, [3](#ijc32498-bib-0003){ref-type="ref"} Many signatures have been reported to be attributable to specific environmental or lifestyle mutagens.[4](#ijc32498-bib-0004){ref-type="ref"} However, somatic mutations could also be influenced by heritable factors,[5](#ijc32498-bib-0005){ref-type="ref"} and endogenous factors that influence cancer far more than previously considered.[6](#ijc32498-bib-0006){ref-type="ref"}, [7](#ijc32498-bib-0007){ref-type="ref"} A few studies have examined the interplay between germline genetics and somatic mutations in carcinogenesis with signals identified for germline variants in *RAD51B*,[8](#ijc32498-bib-0008){ref-type="ref"} *MC1R*,[9](#ijc32498-bib-0009){ref-type="ref"} *APOBEC3* regions[10](#ijc32498-bib-0010){ref-type="ref"}, [11](#ijc32498-bib-0011){ref-type="ref"}, [12](#ijc32498-bib-0012){ref-type="ref"} and DNA mismatch repair genes in different types of cancers.[13](#ijc32498-bib-0013){ref-type="ref"} In addition, a few genes driven by rare deleterious variants were reported to be significant, which include: polymerase epsilon, catalytic subunit (*POLE*) gene associated with the Catalog of Somatic Mutation in Cancer (COSMIC) signature 10 in colorectal and endometrial carcinomas;[1](#ijc32498-bib-0001){ref-type="ref"} homologous recombination deficiency (HRD) genes *PALB2* and *BRCA1/2* associated with HRD signature in various cancers;[14](#ijc32498-bib-0014){ref-type="ref"}, [15](#ijc32498-bib-0015){ref-type="ref"} and nucleotide excision repair (NER) genes associated with COSMiC signature 5 in urothelial tumors.[16](#ijc32498-bib-0016){ref-type="ref"} The existing studies offered some evidences to the largely unexplored relationships between germline and somatic mutations.[10](#ijc32498-bib-0010){ref-type="ref"}, [17](#ijc32498-bib-0017){ref-type="ref"}, [18](#ijc32498-bib-0018){ref-type="ref"}, [19](#ijc32498-bib-0019){ref-type="ref"}

The burden and severity of breast cancer vary widely across populations. Women of African ancestry are more likely to be diagnosed with clinically aggressive disease and have a higher mortality rate than age‐matched women of European or Asian ancestry.[20](#ijc32498-bib-0020){ref-type="ref"} Emerging data from The Cancer Genome Atlas (TCGA) has identified mutation signatures that show differences across ancestry groups.[21](#ijc32498-bib-0021){ref-type="ref"}, [22](#ijc32498-bib-0022){ref-type="ref"} These studies suggest modest differences between African and non‐African ancestry groups but these datasets have relatively small number of women of African ancestry.[23](#ijc32498-bib-0023){ref-type="ref"} To examine the association between common genetic variants, rare deleterious mutations and the contribution of mutational signatures across diverse populations, we used TCGA as the training set, and examined the whole‐genome sequencing (WGS) and whole‐exome sequencing (WES) from Nigeria as the validation set. We tested the hypothesis that biologically relevant germline variants associated with somatic mutation signatures in women of non‐African ancestry would be validated in women of African ancestry as well.

Methods {#ijc32498-sec-0002}
=======

Ethics statement {#ijc32498-sec-0003}
----------------

Our study was embedded within the Nigerian Breast Cancer Study (NBCS) and approved by the Institutional Review Board of all participating institutions. Informed consent has been obtained from the participants.

Training dataset {#ijc32498-sec-0004}
----------------

A total of 1,037 breast cancer patients from TCGA were used as the training set. Demographics of participants, including clinical characteristics across ethnicity are summarized in Supporting Information Table [S1](#ijc32498-supitem-0001){ref-type="supplementary-material"}. Somatic mutation data (single nucleotide variants \[SNVs\]) were generated as previously described.[22](#ijc32498-bib-0022){ref-type="ref"} We included 1,035 WES and 84 WGS, and 82 patients owned both WGS and WES data in this analysis.

### *Common germline variants from genotyping array* {#ijc32498-sec-0005}

Affymetrix Genome‐Wide Human SNP 6.0 Array data for 2,270 breast cancer samples were downloaded from TCGA on November 6, 2015. A total of 1,134 samples were excluded for different reasons (12: missing ID; 1,110: solid tumor tissue; 12: male patients). Among the remaining 1,136 female samples (1,087 unique patients), we excluded samples for 33 more patients due to genotyping missing rate ≥5%, and worked with samples for 1,054 patients. Of the 906,600 single nucleotide polymorphisms (SNPs) included in the microarray data, 1,466 SNPs were excluded for lacking chromosome information or mapping to Y chromosome and 47,140 SNPs were removed due to genotyping missing rate ≥5% or being monomorphic, and 857,994 SNPs remained.

Genetic ancestry of TCGA patients was estimated using principal component analysis (PCA).[21](#ijc32498-bib-0021){ref-type="ref"} According to the estimated proportion of ancestry, patients were grouped into genomic Black (≥50% African ancestry), genomic White (≥90% European ancestry) and genomic Asian (≥90% Asian ancestry) as previously described.[21](#ijc32498-bib-0021){ref-type="ref"}

Genotype imputation was done using IMPUTE2 software with the 1,000 Genomes Project phase 3 integrated variant set as the reference panel.[24](#ijc32498-bib-0024){ref-type="ref"} A total of 81,232,799 SNPs within autosomes were imputed, and 24,570,114 SNPs were kept after excluding singletons or SNPs with an imputation information score \<0.7.

### *Rare deleterious variants from germline exomes* {#ijc32498-sec-0006}

Using the Platypus (<https://www.well.ox.ac.uk/research/research-groups/lunter-group/softwares/platypus-a-haplotype-based-variant-caller-for-next-generation-sequence-data>) in single‐sample mode, variants within exonic regions were called as described previously.[22](#ijc32498-bib-0022){ref-type="ref"} Briefly, variants were considered rare and deleterious if (*i*) they had an allele frequency \<0.05 in The Exome Aggregation Consortium (ExAC)[25](#ijc32498-bib-0025){ref-type="ref"} and across TCGA blood germline exomes from various cancer types,[22](#ijc32498-bib-0022){ref-type="ref"} and (*ii*) they were predicted by variant effect predictor (VEP) to have "HIGH" impact, cause protein loss‐of‐function (stop‐gain, frameshift insertion and deletion \[indel\], etc.), or were missense mutations with a combined annotation dependent depletion (CADD)[26](#ijc32498-bib-0026){ref-type="ref"} score \>25. Only blood germline exomes were included. Additionally, variants were required to fall within consensus coding sequence (CCDS, version 17) exonic regions to be carried downstream. In total, 132,186 rare deleterious variants were found within 11,718 genes in 968 samples, of which 2,933 genes had only one mutation and 6,560 genes (56.0%) had less than five counts of rare coding deleterious variants among these samples. We therefore only focused on genes with at least five mutations (*n* = 5,158) in the downstream analyses. The Bonferroni corrected alpha levels for significance was 9.69 × 10^−6^.

Validation dataset {#ijc32498-sec-0007}
------------------

A total of 172 women with breast cancer from Nigeria were evaluated. All Nigerian patients were assumed to be 100% African with little to no admixture with other populations.[27](#ijc32498-bib-0027){ref-type="ref"} These patients were younger and had more aggressive subtypes of breast cancer with higher proportion of estrogen receptor negative (ER−), progesterone receptor negative (PR−), human epidermal growth factor receptor 2 negative (HER2−; triple‐negative) subtypes. Characteristics of the Nigerian dataset were previously described.[22](#ijc32498-bib-0022){ref-type="ref"}

### *Common and rare genetic variants* {#ijc32498-sec-0008}

Hundred breast tumor samples for WGS and 129 breast tumor samples for WES from 172 unique patients were processed for this analysis. Two WGS samples were excluded as outliers because their mutation counts were \<100. Fifty‐seven patients had both WGS and WES. For the common SNP analysis, 98 WGS samples were involved, while 170 samples (129 WES, 41 WGS) were included for rare variants analysis. Rare coding deleterious variants were called as described above. In total, 22,035 rare coding deleterious variants were found within 5,439 genes in 170 samples, of which 2,196 genes had only one mutation among these samples and 3,876 genes (71.3%) had less than five rare coding deleterious counts. A total of 1,563 genes were included in the final analysis.

Mutation signature calling and comparison with reported signatures {#ijc32498-sec-0009}
------------------------------------------------------------------

### *Mutational signature calling* {#ijc32498-sec-0010}

Somatic SNVs were called as described previously.[22](#ijc32498-bib-0022){ref-type="ref"} Briefly, in order to be utilized in downstream analyses, SNVs needed to be called by both MuTect (<https://software.broadinstitute.org/cancer/cga/mutect>) and Strelka (<https://github.com/Illumina/strelka>) as well as be absent within a normal panel of exomes (*n* = 1,088) and genomes (*n* = 124) derived from blood. We employed a nonnegative matrix factorization (NMF) approach using SomaticSignatures[28](#ijc32498-bib-0028){ref-type="ref"} to extract somatic mutational signatures and estimate their contributions to each sample.

The ability to reliably call mutation signatures depends on having sufficient number of mutations per sample. To this point, we used all high‐quality somatic exome SNVs, regardless of their position in the coding or noncoding region. A pilot study was conducted to compare the stability of signatures among different number of minimum SNVs (24, 48, 72 and 96, data not shown), and found that a cut point of 24 is sufficient. This is consistent with recent finding that 20 mutations gave an average classification accuracy of 80% across signatures.[29](#ijc32498-bib-0029){ref-type="ref"} Any sample containing at least 24 SNVs was included for downstream assessment in order to enlarge the sample size as much as possible.

In order to obtain more stable signature estimates and ensure comparability between the training and validation sets, we combined both datasets to call the signatures, including 84 WGS samples and 1,008 WES samples from TCGA as well as 98 WGS samples and 129 WES samples from Nigeria. For samples with both WGS and WES, both data types were included.

We first used the nonnegative matrix factorization without normalization to obtain the mutation matrix as described by Alexandrov *et al*.,[4](#ijc32498-bib-0004){ref-type="ref"} then calculated the percentage contributions of signatures for each sample by normalizing to the number of mutations of each sample. For subsequent analyses, we used the percentage of mutations assigned to each signature (contribution) rather than the total number of mutations attributed to a signature.[30](#ijc32498-bib-0030){ref-type="ref"} The sum of mutation signatures' contribution is 1. This distinction is important as high APOBEC contribution, for example, do not necessarily imply APOBEC hypermutation.

Nine signatures were retained at the end for further downstream analyses because nine signatures explained approximately 99% of variance in the current sample. For all nine signatures, we examined the correlation of contributions between exomes and genomes using 138 individuals who had both WES and WGS data using intraclass correlation coefficient (rho). Each signature\'s contribution was simultaneously called for WGS samples and WES samples for those 138 individuals. Signatures A1 (rho = 0.938), A2 (rho = 0.912) and A9 (rho = 0.866) all exhibited strong correlation). APOBEC C\>T (Signature A1) and C\>G (Signature A2) contributions were correlated (*r* = 0.43). We only focused on stable signatures between WGS and WES in order to reliably leverage all available WES samples.

### *Comparison with reported signatures* {#ijc32498-sec-0011}

We compared our mutation signature matrices with the 30 previously reported signatures operative across a variety of cancer types downloaded from the COSMIC. Mean Kullback--Leibler Divergence was applied to evaluate the similarity between our signatures and those from COSMIC:[31](#ijc32498-bib-0031){ref-type="ref"} $${KL}\left( {P,Q} \right) = \frac{1}{2}\left( {\sum\limits_{i = 1}^{96}P_{i}\ln\frac{P_{i}}{Q_{i}} + \sum\limits_{i = 1}^{96}Q_{i}\ \ln\frac{Q_{i}}{P_{i}}} \right).$$ *P* and *Q* are the distributions matrixes for our signatures and those from COSMIC, respectively. The smaller Kullback--Leibler Divergence is, the better the similarity. A similarity of 0.00 is an exact match. With this approach, we determined the best representative known COSMIC signature for each of the signature we identified, and named with the name from canonical COSMIC signature they most closely resemble. Two signatures A5 and A7 did not match any canonical COSMIC signature.

Statistical analysis {#ijc32498-sec-0012}
--------------------

### *Signature contributions by demographic and clinical characteristics* {#ijc32498-sec-0013}

We compared contribution of the selected signatures among categorical variables, including ancestry (Black, White, Nigerian) and hormone receptor (HR)/HER2 status (HER2+, HR+/HER2− and HR−/HER2−), using Mann--Whitney U test.

### *Heritability estimation of mutation signatures using GCTA* {#ijc32498-sec-0014}

We used GCTA to calculate the pairwise genetic relationship between individuals and created the genetic relationship matrix (GRM).[32](#ijc32498-bib-0032){ref-type="ref"} We used a GRM cut‐off value of 0.05,[33](#ijc32498-bib-0033){ref-type="ref"} which excludes relationships that are approximately closer than second cousins. This removed around 77 samples in the TCGA dataset. All the heritability estimation analyses control for first 10 eigenvectors from PCA. We then estimated PCA‐adjusted heritability of each phenotype (signature contribution) by the restricted maximum likelihood method in GCTA. Power analysis (<http://cnsgenomics.com/shiny/gctaPower/>) indicated a 99% chance of detecting a SNP‐based heritability estimate (*h* ^2^) of 0.15 in the TCGA cohort.[34](#ijc32498-bib-0034){ref-type="ref"}

The heritability was not calculated for Nigeria samples due to limited sample size. In the training dataset, among 24,570,114 SNPs, 1,573,566 were removed due to missing genotype data (missing proportion \>5%), 5,301,200 variants were removed due to minor allele frequency (MAF) \<0.001, and 188,864 variants were removed due to deviation from the Hardy--Weinberg equilibrium (HWE). The remaining 17,506,484 SNPs were used for downstream analyses. Among 1,054 samples with SNP chip data, 178 samples were removed due to missing genotype data (cut‐off point as 1%), 77 were removed when pruning the GRM (relatedness \<0.05) and 66 samples were excluded due to missing mutation signature. In the end, 733 samples were included in the model.

### *Association of common SNPs with signature contribution* {#ijc32498-sec-0015}

For TCGA, we analyzed 7,177,790 common SNPs with MAF ≥0.05. The single‐SNP association tests with signature contribution were conducted using linear regression as implemented in SNPtest,[35](#ijc32498-bib-0035){ref-type="ref"} with adjustment for age and the eigenvectors from PCA. For the validation data, on the other hand, we only adjusted for age given that we do not anticipate any admixture with other ethnic. We applied genome‐wide association study (GWAS) threshold (*p* = 5 × 10^−8^) as our cut‐off point in the discovery stage. We also filtered the association results of the GWAS‐identified risk SNPs by its location within the autosomal regions to check their role in the signature contributions. All SNPs included were previously reported to be associated with breast cancer risk (<https://www.ebi.ac.uk/gwas/>). In Nigerians, we only assessed SNPs that were nominally significant in the TCGA cohort.

### *Association of rare deleterious variants with signature contribution* {#ijc32498-sec-0016}

Gene‐based association analyses for mutation signatures were conducted using the unified optimal sequence kernel association test (SKAT‐O),[36](#ijc32498-bib-0036){ref-type="ref"} as implemented in SKAT.[37](#ijc32498-bib-0037){ref-type="ref"} As a linear combination of the burden and SKAT tests,[38](#ijc32498-bib-0038){ref-type="ref"} SKAT‐O achieves robust power whether a given gene has a high proportion of causal variants exerting effects in the same direction, or instead has many noncausal variants or variants exerting effects in opposite directions.[39](#ijc32498-bib-0039){ref-type="ref"} We considered weighting parameter θ = 1 (burden) and θ = 0 (SKAT) tests and reported the optimal of the two tests. We included putatively deleterious variants with MAF ≤5%, and used the beta distribution weights proposed by Wu *et al*.,[38](#ijc32498-bib-0038){ref-type="ref"} which upweights rarer variants, for both tests. Gene‐based analyses were adjusted for age and the eigenvectors from PCA for TCGA data. For validation with Nigerian dataset, we only adjusted for age. Subgroup analyses by subtype were also evaluated for all significant results. We used a Bonferroni adjustment for multiple testing to assess the significance of the gene‐based test results. We also calculate Benjamini--Hochberg\'s false positive rate in the discovery dataset. For genes with evidences of association in the discovery phase, we pooled data from TCGA and Nigeria and conducted SKAT‐O analysis after adjusting for age and proportion of African and Asian ancestry.

Two combined gene sets were examined to test their association with the contribution of HRD signature. One is a set of known breast cancer predisposition genes (BROCA gene panel: <http://tests.labmed.washington.edu/BROCA>), another one contained all homologous recombination related genes from Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, including [*atm*, *rad51c*, *bard1*, *brca1*, *brca2*, *brip1*, *fam175a*, *mre11a*, *nbn*, *palb2*, *xrcc2*, *pold1*, *rad51b*, *babam1*, *blm*, *bre*, *eme1*, *rad50*, *rad52*, *rad54b*, *rad54l*, *rbbp8*, *rpa1*, *sycp3*, *top3a*, *top3b*, *topbp1*, *uimc1*]{.smallcaps} and [*xrcc3*.]{.smallcaps} All statistical calculations were completed in R or Stata version 15.0 (College Station, TX). All *p* values are two‐sided.

Results {#ijc32498-sec-0017}
=======

Basic information {#ijc32498-sec-0018}
-----------------

A total of 1,011 samples with somatic mutation count ≥24 (1,008 WES, 84 WGS) from TCGA were included as the training dataset, and 170 samples that satisfied the same criteria from Nigeria (129 WES, 98 WGS) were involved as the validation set (Fig. [1](#ijc32498-fig-0001){ref-type="fig"}). The median (25th quartile and 75th quartile) for somatic mutation count per WES sample were 73 (50--144) for TCGA Caucasians, 100 (63--194) for TCGA African Americans and 131 (64--241) for Nigerians (Supporting Information Table [S1](#ijc32498-supitem-0001){ref-type="supplementary-material"} and Fig. [S1](#ijc32498-supitem-0001){ref-type="supplementary-material"}). The number of mutation from WES was highly correlated with that from WGS (*p* \< 0.001, Supporting Information Fig. [S1](#ijc32498-supitem-0001){ref-type="supplementary-material"}C).

![Flow chart of this study. \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](IJC-145-3321-g001){#ijc32498-fig-0001}

Nine mutational signatures were extracted (Supporting Information Fig. [S2](#ijc32498-supitem-0001){ref-type="supplementary-material"}). Our signatures closely resembled breast cancer signatures from COSMiC: signatures A1 (S2: APOBEC C\>T), A2 (S13: APOBEC C\>G), A3 (S17: Unknown, breast cancer related), A4 (S10: Altered activity of polymerase POLE), A6 (S1: Aging), A8 (S8: Unknown etiology) and A9 (S9: HRD; Supporting Information Fig. [S3](#ijc32498-supitem-0001){ref-type="supplementary-material"}). The common signatures including S2 (APOBEC C\>T), S13 (APOBEC C\>G), S1 (Aging), S8 (Unknown etiology) and S9 (HRD), explained the vast majority of mutations regardless of ethnicity or subtype (Supporting Information Figs. [S4](#ijc32498-supitem-0001){ref-type="supplementary-material"}). The correlation between exomes and genomes were presented in Supporting Information Figures [S5](#ijc32498-supitem-0001){ref-type="supplementary-material"}---there was high correlation for S2, S13, S1 and S9. Given the robustness of signature calls between these two data types, we focused on these four signatures for subsequent analyses.

Heritability of selected signatures' contribution {#ijc32498-sec-0019}
-------------------------------------------------

The estimates of array‐based heritability, *h* ^2^, ranged from 0.040 to 0.575 in TCGA samples across four selected signatures (Table [1](#ijc32498-tbl-0001){ref-type="table"}), with APOBEC C\>T signature (*h* ^2^ = 0.575, *p* = 0.010) and combined APOBEC signature (*h* ^2^ = 0.432, *p* = 0.042) displaying the strongest heritable components. Of note, the heritability estimates of mutation signatures are unreliable due to limited sample size, although we showed that some of them were statistically significantly different from zero.

###### 

GWAS estimates of signature heritability for signature contributions in TCGA dataset

                                                                                  Adjusted PCA, 733 samples (excluding relatedness)                                           
  ------- ----------------------------------------------------------------------- --------------------------------------------------- ------- ------- ------- ------- ------- -----------
  1       APOBEC of cytidine deaminases (C\>T)                                    0.011                                               0.006   0.008   0.004   0.575   0.254   **0.010**
  2       APOBEC (C\>G)                                                           0.001                                               0.004   0.010   0.002   0.108   0.307   0.350
  1 + 2   APOBEC                                                                  0.022                                               0.016   0.028   0.010   0.432   0.272   **0.042**
  6       Spontaneous deamination of 5‐methylcytosine                             0.001                                               0.011   0.034   0.007   0.040   0.313   0.445
  9       Failure of DNA double‐strand break‐repair by homologous recombination   0.004                                               0.012   0.026   0.007   0.154   0.358   0.349

*Note*: In TCGA, among 24,570,114 SNPs, 1,573,566 variants were removed due to missing genotype data (geno = 0.05), 5,301,200 variants were removed due to minor allele threshold (MAF, 0.001) and 188,864 variants were removed due to Hardy--Weinberg exact test. A total of 17,506,484 SNPs were kept in the end. Among 1,054 samples with GWAS information, 178 samples were removed due to missing genotype data (mind = 0.01), 77 were removed when pruning the GRM (relatedness = 0.05) and 66 samples were excluded due to missing of mutation signature. In the end, we have 733 samples in the model. Bold *p* values denote statistical significance at the *p* \< 0.05.

Association of common SNPs with signature contribution {#ijc32498-sec-0020}
------------------------------------------------------

Next, we analyzed the association of common SNPs with mutation signatures. Nine hundred seventy‐four samples from TCGA and 170 samples from Nigeria with mutation signature results were further analyzed. No SNPs in TCGA showed significant association beyond genome‐wide significance level contributing to any of the four selected signatures (Supporting Information Fig. [S6](#ijc32498-supitem-0001){ref-type="supplementary-material"}). When contributions from the two APOBEC signatures were combined together, seven SNPs on or near *GNB5* showed evidence of association surpassing *p* \< 5 × 10^−8^ (Fig. [2](#ijc32498-fig-0002){ref-type="fig"} *a*, Table [2](#ijc32498-tbl-0002){ref-type="table"}). rs66866642/rs578194564 (MAF = 0.169) in the intronic region of the *GNB5* gene (Fig. [2](#ijc32498-fig-0002){ref-type="fig"} *b*) had the strongest association, and this signal was also consistently observed for both APOBEC C\>T and APOBEC C\>G signatures (Supporting Information Fig. [S7](#ijc32498-supitem-0001){ref-type="supplementary-material"}). The CT allele of rs66866642/rs578194564 was significantly associated with a 35.3% absolute increase in the contribution to APOBEC signature (95% confidence interval \[CI\]: 23.1--47.5, *p* = 1.03 × 10^−8^; Table [2](#ijc32498-tbl-0002){ref-type="table"}, Fig. [2](#ijc32498-fig-0002){ref-type="fig"} *c*). The top seven SNPs in TCGA tagged a couple of SNPs having LD *r* ^2^ ≥ 0.85, and they are located in the region with several regulatory elements (Supporting Information Table [S2](#ijc32498-supitem-0001){ref-type="supplementary-material"}, Fig. [2](#ijc32498-fig-0002){ref-type="fig"} *d*). Using the Nigerian cohort as the validation set, 13 of 30 top SNPs were detected with nonsignificant *p* values, but with consistent magnitude and direction in beta coefficients to those in TCGA (Table [2](#ijc32498-tbl-0002){ref-type="table"}).

![Common SNP rs66866642/rs578194564 in *GNB5* is associated with APOBEC signatures. (*a*) Manhattan plot for associations between common SNPs and APOBEC signatures. (*b*) Plot of log‐transformed *p* values from single marker analysis for the *GNB5* gene. The labeled marker, a purple diamond (rs66866642/rs578194564), is the most significant SNP (index SNP). The LD between the index SNP and other markers in the region was color coded, with red color indicating strong LD (*r* ^2^ \> 0.8) and blue color indicating weak LD (*r* ^2^ \< 0.2). (*c*) Genotype of rs66866642/rs578194564 among different ethnic groups. (*d*) Functional elements at the *GNB5* gene region. Data is from ENCODE through UCSC Genome Browser, including histone modification marks for H3K4Me1 and H3K27Ac, transcription factor binding sites and DNase hypersensitivity sites of human mammary epithelial cells (HMEC), breast cancer cell (MCF7). \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](IJC-145-3321-g002){#ijc32498-fig-0002}

###### 

The top 30 signal for common SNPs in association tests with combined APOBEC signature contributions

  ID   SNP                      Chromosome   Position (base)   Ref allele   ALT allele   TCGA    Nigeria[1](#ijc32498-note-0005){ref-type="fn"}                                                          
  ---- ------------------------ ------------ ----------------- ------------ ------------ ------- ------------------------------------------------ -------------- ------- ------- ------- ------- ------- -------
  1    rs66866642/rs578194564   15           52,444,832        C            CT           0.948   0.169                                            **1.03E‐08**   0.353   0.062   --      --      --      --
  2    rs12902073               15           52,447,508        G            A            0.986   0.170                                            **2.84E‐08**   0.334   0.060   --      --      --      --
  3    rs12440354               15           52,452,434        T            C            0.983   0.175                                            **3.90E‐08**   0.328   0.060   --      --      --      --
  4    rs12901730               15           52,452,697        T            A            0.983   0.171                                            **4.31E‐08**   0.330   0.060   --      --      --      --
  5    rs12901891               15           52,452,834        T            C            0.983   0.171                                            **4.33E‐08**   0.330   0.060   --      --      --      --
  6    rs12438743               15           52,454,098        C            T            0.982   0.171                                            **4.38E‐08**   0.330   0.060   --      --      --      --
  7    rs373292393              15           52,440,257        C            CAA          0.983   0.155                                            **4.98E‐08**   0.340   0.062   --      --      --      --
  8    rs12910398               15           52,445,477        C            T            0.987   0.176                                            5.57E‐08       0.322   0.059   0.051   0.239   0.390   0.331
  9    rs12905698               15           52,445,090        A            G            0.986   0.176                                            6.16E‐08       0.321   0.059   0.051   0.239   0.390   0.331
  10   rs12909880               15           52,449,293        T            C            0.982   0.173                                            6.76E‐08       0.323   0.060   --      --      --      --
  11   rs12902522               15           52,448,036        A            G            0.986   0.177                                            7.59E‐08       0.319   0.059   0.051   0.239   0.390   0.331
  12   rs12909184               15           52,450,617        G            T            0.983   0.178                                            7.91E‐08       0.319   0.059   0.051   0.239   0.390   0.331
  13   rs12910052               15           52,449,360        T            C            0.983   0.178                                            7.98E‐08       0.318   0.059   0.051   0.239   0.390   0.331
  14   rs12903769               15           52,449,733        G            A            0.982   0.167                                            8.20E‐08       0.327   0.061   --      --      --      --
  15   rs12908833               15           52,449,195        G            C            0.982   0.174                                            8.80E‐08       0.320   0.060   --      --      --      --
  16   rs12908742               15           52,449,379        A            C            0.982   0.174                                            8.82E‐08       0.320   0.060   0.051   0.239   0.390   0.331
  17   rs3794543                15           52,441,524        C            T            0.993   0.158                                            1.07E‐07       0.327   0.061   --      --      --      --
  18   rs4776007                15           52,447,299        A            G            0.987   0.185                                            1.29E‐07       0.308   0.058   0.097   0.203   0.323   0.254
  19   rs8034097                15           52,437,278        A            G            0.995   0.151                                            1.32E‐07       0.330   0.063   --      --      --      --
  20   rs12438274               15           52,439,368        T            G            0.971   0.188                                            1.33E‐07       0.311   0.059   --      --      --      --
  21   rs12438194               15           52,439,096        T            A            0.993   0.152                                            1.35E‐07       0.330   0.063   --      --      --      --
  22   rs4636859                15           52,435,696        T            C            0.996   0.151                                            1.45E‐07       0.329   0.063   --      --      --      --
  23   rs12438937               15           52,441,686        C            T            0.992   0.170                                            1.79E‐07       0.313   0.060   0.092   0.216   0.320   0.259
  24   rs35709612               15           52,439,940        A            C            0.994   0.169                                            1.80E‐07       0.313   0.060   0.092   0.208   0.326   0.259
  25   rs35448038               15           52,434,758        GT           G            0.981   0.163                                            1.89E‐07       0.317   0.061   --      --      --      --
  26   rs12593041               15           52,443,107        C            T            0.988   0.171                                            2.49E‐07       0.310   0.060   0.097   0.203   0.323   0.254
  27   rs62014722               15           52,434,338        C            G            0.995   0.163                                            2.52E‐07       0.313   0.061   0.056   0.130   0.481   0.318
  28   rs62014721               15           52,434,284        C            G            0.994   0.163                                            2.53E‐07       0.313   0.061   0.056   0.130   0.481   0.318
  29   rs4238384                15           52,436,334        C            T            1.000   0.222                                            2.75E‐07       0.281   0.055   0.276   0.227   0.212   0.175
  30   rs71130134               15           52,437,673        CA           C            0.980   0.157                                            4.73E‐07       0.313   0.062   --      --      --      --

Bold *p* values denote statistical significance at the *p* \< 5 × 10^−8^ (genome‐wide association study threshold).

A total of 17 SNPs were not covered in WES samples, so we filled the corresponding cell with "--".

Abbreviation: MAF, minor allele frequency.

In addition, we evaluated the association between index SNPs identified in previous GWAS of breast cancer risk, and signatures contribution. We found a dozen SNPs associated at nominal significance level with either APOBEC signature or HRD signature (Supporting Information Table [S3](#ijc32498-supitem-0001){ref-type="supplementary-material"}). The genes tagged by SNPs associated with APOBEC signature included *ANKRD16*, *ZNF365*, *CHST9*, *ARRDC3*, *FGFR2* and *ESR1*. Most of the genes associated with HRD signature function to decrease homologous recombination repair frequency, including *RNF11*5, *ANXA13*, *DNAJC1*, *DNAH11* and *TFAP2A*.

Associations between rare deleterious variants and signature contribution {#ijc32498-sec-0021}
-------------------------------------------------------------------------

Manhattan plots for the gene‐based association analyses are shown in Figure [3](#ijc32498-fig-0003){ref-type="fig"}a and Supporting Information Figure [S8](#ijc32498-supitem-0001){ref-type="supplementary-material"} for selected mutation signatures in TCGA cohort. Five genes showed evidence of association with contribution of APOBEC C\>T signature or APOBEC C\>G signature surpassing defined significance level (threshold as 9.69 × 10^−6^, Table [3](#ijc32498-tbl-0003){ref-type="table"}). *MTCL1* is the top signal for combined APOBEC signature (pooled *p* = 6.11 × 10^−6^), and women with *MTCL1* mutations had higher APOBEC signature contribution. Two additional genes (*HIVEP1* and *TMEM104*) had marginal nominal significant association with contribution of combined APOBEC signature in both datasets. As the direction of the association for *HIVEP1* was consistent across the TCGA and Nigerian datasets (pooled *p* = 0.0009), while the *TMEM104* association was positive in the TCGA cohort but negative in the Nigerian cohort (pooled *p* = 0.079) (Supporting Information Fig. [S9](#ijc32498-supitem-0001){ref-type="supplementary-material"}), suggesting *HIVEP1* is likely a true association but *TMEM104* may be false negative. Mutations in three genes, including *MTCL1*, *ERC1* and *HIP1*, were associated with higher contribution of APOBEC C\>G signature alone.

![Associations between rare deleterious variants and HRD signature. (*a*) Plot of log‐transformed *p* values from gene‐based analysis for rare deleterious variants. (*b*--*d*) Comparison of contribution of HRD signature, grouped by breast cancer tissue subgroups, datasets, and the number of *BRCA1* (*b*), *BRCA2* (*c*) and *BRCA1*/*BRCA2* mutations (*d*). \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](IJC-145-3321-g003){#ijc32498-fig-0003}

###### 

Significant results of gene‐based analysis in the training and validation datasets

  Signatures    Gene        TCGA data       Nigeria data   Pooled data                     
  ------------- ----------- --------------- -------------- ------------- ---- -------- --- ------------------------
  APOBEC C\>T   *ATP13A1*   9.04 × 10^−6^   0.006          1             5    0.580    5   0.0089
                *ERC1*      0.186           1.000          1             9    0.442    1   0.282
                *HIP1*      0.773           1.000          1             13   0.494    2   1.000
                *QARS*      0.0023          1.154          0             6    0.434    1   0.0036
                *MTCL1*     5.21 × 10^−5^   0.053          0             16   0.538    2   0.0005
                *HIVEP1*    0.149           1.000          1             20   0.0657   9   0.0798
                *TMEM104*   0.0002          0.061          0             15   0.156    7   0.0609
  APOBEC C\>G   *ATP13A1*   0.356           1.000          1             5    0.737    5   0.580
                *ERC1*      4.45 × 10^−7^   0.0005         0             9    0.444    1   **1.63 × 10** ^**−7**^
                *HIP1*      3.46 × 10^−6^   0.005          0             13   0.219    2   **9.18 × 10** ^**−7**^
                *QARS*      6.46 × 10^−7^   0.001          0             6    0.740    1   2.86 × 10^−5^
                *MTCL1*     1.35 × 10^−6^   0.001          0             16   0.360    2   **4.21 × 10** ^**−7**^
                *HIVEP1*    2.23 × 10^−5^   0.015          0             20   0.119    9   2.57 × 10^−5^
                *TMEM104*   0.0095          0.417          1             15   0.0238   7   0.0445
  APOBEC        *ATP13A1*   0.1274          0.883          1             5    0.611    5   0.507
                *ERC1*      0.0006          0.165          0             9    0.957    1   0.0014
                *HIP1*      0.0154          0.452          0             13   0.808    2   0.0075
                *QARS*      1.50 × 10^−5^   0.056          0             6    0.520    1   0.0002
                *MTCL1*     1.91 × 10^−6^   0.012          1             16   0.393    2   **6.11 × 10** ^**−6**^
                *HIVEP1*    0.0024          0.253          1             20   0.054    9   0.0009
                *TMEM104*   0.0004          0.189          1             15   0.041    7   0.079
  HRD           *BRCA1*     1.03 × 10^−8^   0.0001         1             25   0.139    6   **7.02 × 10** ^**−9**^
                *BRCA2*     1.05 × 10^−5^   0.008          1             50   0.014    8   **7.93 × 10** ^**−7**^
                *COL15A1*   5.15 × 10^−6^   0.005          0             10   0.391    1   **5.50 × 10** ^**−6**^
                *PIGO*      1.80 × 10^−5^   0.009          0             5    --       0   **8.68 × 10** ^**−6**^

Bold *p* values denote statistical significance at the *p* \< 9.69 × 10^−6^ (Bonferroni corrected alpha level).

The weighting parameter theta indicates whether the SKAT test (theta = 0) or burden test (theta = 1) gave the smallest *p* value.

*p* value from optimal sequence kernel association test (SKAT‐O).

Germline mutations in four genes, *BRCA1*, *BRCA2*, *COL15A1* and *PIGO*, were significantly associated with contributions from the HRD signature (all *p* ≤ 5.5 × 10^−6^). The contribution of HRD signature was consistently increasing along with the number of rare deleterious variants in both *BRCA1* and *BRCA2* across different tumor subtypes (HER2+, HR+/HER2− and HR−/HER2+) and different datasets (Figs. [3](#ijc32498-fig-0003){ref-type="fig"} *b* and [3](#ijc32498-fig-0003){ref-type="fig"} *c*). We combined all mutations in *BRCA1* and *BRCA2* together. The combined gene set was significantly associated with the contribution to HRD signature in both TCGA (*p* = 5.0 × 10^−12^) and Nigeria samples (*p* = 0.0036). This association was also highly consistent across different tumor subtypes and datasets (Fig. [3](#ijc32498-fig-0003){ref-type="fig"} *d*). Despite genome‐wide significance, mutations in *COL15A1* and *PIGO* are rare and further validation of their associations is desirable.

In addition, when we combined all mutations occurring in a set of known breast cancer predisposition genes (BROCA gene panel; 17 genes), or when we merged all homologous recombination related genes (29 genes), we found that both compounded gene sets were significantly associated with the contribution of HRD signature (*p* = 2.6 × 10^−7^ and 2.8 × 10^−5^, respectively). The significance level remained in the validation set (*p* = 0.0007 and 0.014, respectively). However, after excluding *BRCA1* and *BRCA2*, neither of these gene sets remained significantly associated with HRD signature contribution. Two of HR related genes, *BRIP1* and *RAD50*, probably contributed to the association signal since many Nigerian samples had HRD contributions present yet no germline mutation in BROCA or homologous recombination genes (Supporting Information Table [S4](#ijc32498-supitem-0001){ref-type="supplementary-material"}).

Discussion {#ijc32498-sec-0022}
==========

Using breast cancer data from 1,011 patients from TCGA (the training set) and 170 Nigerian women (the validation set), we extracted four stable mutational signatures including APOBEC C\>T, APOBEC C\>G, aging and HRD, which is consistent with previous studies.[1](#ijc32498-bib-0001){ref-type="ref"}, [4](#ijc32498-bib-0004){ref-type="ref"}, [40](#ijc32498-bib-0040){ref-type="ref"}, [41](#ijc32498-bib-0041){ref-type="ref"} These signatures alone were able to explain the majority of the tumor mutations across both cohorts. Heritability analysis suggests that germline genetic factors could explain some of the heterogeneity in mutation signatures across patients with breast cancer. We confirmed the association between rare deleterious variants in *BRCA1*/*2* and increased HRD signature activity. We found that common variants proximal to *GNB5* as well as rare exonic mutations within *MTCL1* were associated with increased APOBEC C\>T/G activity, acting as plausible contributors to the observed heritability. Rare variants in *HIVEP1* were also marginally associated with the signature although this did not reach genome‐wide significance, probably because of the small sample size.

APOBEC signatures, the most widespread mutational signatures in human cancers, have been reported in 16 of 30 tumor types from TCGA, implicating APOBEC enzymes as some of the most pervasive mutators in human cancers.[10](#ijc32498-bib-0010){ref-type="ref"} We found seven common SNPs in/near *GNB5* to be significantly associated with APOBEC signature contribution in TCGA. However, this signal could not be replicated in Nigerians, possibly due to limited sample size. Previous studies suggested a potential role for *GNB5* in cancer. First, *GNB5* encodes guanine nucleotide‐binding protein beta‐5, and this protein is expressed in breast tissue.[42](#ijc32498-bib-0042){ref-type="ref"} Evidence from the Human Protein Atlas at the protein and mRNA levels also suggested the favorable prognostic role of GNB5 in renal cancer and endometrial cancer. Second, overexpression of *GNB5* promoted a migratory phenotype in lung adenocarcinoma cells.[43](#ijc32498-bib-0043){ref-type="ref"} However, it remains unclear whether GNB5 directly affects the transcription, translation or activity of APOBEC enzymes. Further molecular analyses are required to functionally characterize the observed relationship and its generalizability to other tumor types.

The association between *HIVEP1* and APOBEC signature could be explained by their functional roles in viral defense.[44](#ijc32498-bib-0044){ref-type="ref"}, [45](#ijc32498-bib-0045){ref-type="ref"} The presence of viral element can stimulate APOBEC expression through a complex network of innate immunity signaling, including components like Toll‐like receptors, interferons, interleukins and even P53.[46](#ijc32498-bib-0046){ref-type="ref"} It is possible that HIVEP1 proteins play a more direct role in APOBEC regulation as it binds enhancer elements containing the GGGACTTTCC motif.[47](#ijc32498-bib-0047){ref-type="ref"} In the context of disease, downregulation of another family member, *HIVEP2* gene, has already been shown as one of the genetic events responsible for breast cancer.[48](#ijc32498-bib-0048){ref-type="ref"} We did not find prior evidence directly implicating *MTCL1*, also known as suppressor of glucose autophagy associated 2 (SOGA2), in APOBEC activity. Suggestive association between *MTCL1* and breast cancer risk has been reported in women of Indonesian ancestry, further indicating the potential importance of germline variation proximal to this gene.[49](#ijc32498-bib-0049){ref-type="ref"} To further understand the biological basis of our observations, it will be necessary to conduct functional studies to uncover the exact causal mechanisms that may ultimately inform innovative therapeutic approaches.

We found that the combined effects of rare, deleterious alleles in *BRCA1* and *BRCA2* were consistently associated with higher HRD signature contributions in both TCGA and Nigerian data. This finding was in accordance with other studies done with prostate and gastric cancers,[1](#ijc32498-bib-0001){ref-type="ref"}, [14](#ijc32498-bib-0014){ref-type="ref"}, [15](#ijc32498-bib-0015){ref-type="ref"} and the mechanisms promoting HRD activity have been explored in several experimental studies.[30](#ijc32498-bib-0030){ref-type="ref"}, [41](#ijc32498-bib-0041){ref-type="ref"}, [50](#ijc32498-bib-0050){ref-type="ref"}, [51](#ijc32498-bib-0051){ref-type="ref"}, [52](#ijc32498-bib-0052){ref-type="ref"} However, to the best of our knowledge, this is the first report of association in an indigenous African population in Nigeria, and our findings could have significant implications for cancer control in underserved and underrepresented population with higher burden of aggressive young onset breast cancer.[20](#ijc32498-bib-0020){ref-type="ref"}

In previous work, Zhu and colleagues observed a significant inverse association (*p* = 8.75 × 10^−6^) between the risk allele in rs2588809 of the gene *RAD51B* and total somatic mutation count across 638 breast cancer patients of European ancestry from TCGA.[8](#ijc32498-bib-0008){ref-type="ref"} In our study, rs2588809 was not associated with the contribution of any signatures, but rare deleterious variants within *RAD51B* were found to be nominal significantly correlated with the contributions of aging and HRD signatures. It has been shown that loss‐of‐function mutations in homologous recombination genes other than *BRCA1/2* can facilitate HRD signature activity.[41](#ijc32498-bib-0041){ref-type="ref"} It is possible that *RAD51B* deficiency increases the mutational burden of tumors through HRD, potentially making these patients good candidates for immunotherapy due to their increased likelihood of harboring neoantigens.[53](#ijc32498-bib-0053){ref-type="ref"} Taken together, these findings suggest that genetic ancestry may play an important role in mutational development and cancer progression. This highlights the need to accumulate more genetic data from diverse populations in order to better understand the heightened aggressive breast cancer risk observed in individuals of African ancestry.[54](#ijc32498-bib-0054){ref-type="ref"}

There are multiple advantages in our study. First, samples from Nigeria added a substantial value in terms of validation, which expanded the findings from a primarily US European ancestry population to an indigenous African population.[55](#ijc32498-bib-0055){ref-type="ref"} Second, we harmonized data from a number of sources using the same pipeline, which avoided batch effect due to bioinformatics software. Third, we inferred mutations signatures across all samples using nonnegative matrix factorization and used the estimated signature contributions directly for analysis. This offered advantages over previous approaches which used the burden of mutations found in specific trinucleotide contexts as a proxy for APOBEC signature activity.[3](#ijc32498-bib-0003){ref-type="ref"}, [8](#ijc32498-bib-0008){ref-type="ref"}, [56](#ijc32498-bib-0056){ref-type="ref"}, [57](#ijc32498-bib-0057){ref-type="ref"} Fourth, we comprehensively explored the association between common genetic variants, rare deleterious variants and the contribution of mutational signatures across different ethnicities, and provided insights to the relationship between germline variants and somatic mutational processes.[10](#ijc32498-bib-0010){ref-type="ref"} Several study limitations should also be noted. First, we only focused on the substitutions, and did not consider other types of somatic mutation, such as indels and structural variants.[3](#ijc32498-bib-0003){ref-type="ref"}, [41](#ijc32498-bib-0041){ref-type="ref"} Second, while WES allowed us to acquire a larger number of data, our analyses were confined to somatic mutations within protein coding regions. WGS could uncover microscale and macroscale somatic alterations[58](#ijc32498-bib-0058){ref-type="ref"} and provide us more stable estimates of mutation signature contributions. As such, we only focused on the four signatures with strong concordance between WGS data and WES data. Although common practice,[1](#ijc32498-bib-0001){ref-type="ref"}, [22](#ijc32498-bib-0022){ref-type="ref"} estimating mutation signatures from exome sequencing could cause potential biases due to sequence motif representation as compared to whole genome. APOBEC enzymes have been shown to preferentially target genic regions, which is likely due to the availability of ssDNA substrates during transcription.[59](#ijc32498-bib-0059){ref-type="ref"}, [60](#ijc32498-bib-0060){ref-type="ref"}, [61](#ijc32498-bib-0061){ref-type="ref"} Additional work has demonstrated that APOBEC mutations are also enriched within early‐replicating regions regardless of transcriptional activity.[60](#ijc32498-bib-0060){ref-type="ref"} It is unclear if identical mutagenic processes affect all early‐replicating and transcriptionally active regions. Even though we observed high mutation signature correlations between exomes and genomes, we cannot rule out the possibility that different molecular mechanisms generated similar mutational signatures in coding and noncoding regions. It is also possible that a single mutational process is responsible for generating somewhat different signatures in these regions. As such, it is important to remember that signature contribution estimates only serve as a phenotypic marker and may not fully capture the nuances of underlying mechanistic processes. Third, causal links between germline and somatic mutational processes are one explanation for the associations presented here, but other explanations cannot be ruled out.[30](#ijc32498-bib-0030){ref-type="ref"}

Conclusions {#ijc32498-sec-0023}
===========

In summary, our study identified associations between germline variants and mutational patterns in breast cancer across different ethnicities, especially in African women for the first time. This finding may advance our understanding of breast cancer etiology with potential implications for prevention and treatment. However, further replications in larger and diverse populations are needed to validate our findings. Meanwhile, future work focused on understanding the biological basis of cancer susceptibility alleles will be instrumental in better understanding the complex interplay between germline genetics and somatic mutations.
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